Zydus Cadila on November 20, 2015 launched Tenglyn (teneligliptin 20 mg) tablet, which belongs to a new class of oral anti-diabetic agents - gliptins. With an aim to make this important therapy affordable and accessible to diabetic patients, Tenglyn is being priced at just Rs 7 per tablet which is almost 1/6th the price at which the gliptins were initially launched in India, claims Zydus Cadila.
Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management. Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycemia, GI side effects, lactic acidosis, weight gain, CV risks, etc, which pose a major challenge in the treatment of diabetes.
Dr Sharvil Patel, deputy managing director, Zydus Cadila, said, “At Zydus, our endeavour has been to bring new therapies and innovations that address the two primary challenges in India of accessibility and affordability. Diabetes, as we know is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost.”
The group had earlier launched Lipaglyn (saroglitazar), India's first NCE which is a breakthrough therapy in the treatment of diabetic dyslipidemia and hypertriglyceridemia.
Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management. Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycemia, GI side effects, lactic acidosis, weight gain, CV risks, etc, which pose a major challenge in the treatment of diabetes.
Dr Sharvil Patel, deputy managing director, Zydus Cadila, said, “At Zydus, our endeavour has been to bring new therapies and innovations that address the two primary challenges in India of accessibility and affordability. Diabetes, as we know is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost.”
The group had earlier launched Lipaglyn (saroglitazar), India's first NCE which is a breakthrough therapy in the treatment of diabetic dyslipidemia and hypertriglyceridemia.